Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model

Molecular Psychiatry

Volumn 18, Issue 8, 2013, Pages 889-897

  Steele, J W ^a,b,c   Lachenmayer, M L ^a,d   Ju, S ^e   Stock, A ^a   Liken, J ^e   Kim, S H ^a,b   Delgado, L M ^f   Alfaro, I E ^g   Bernales, S ^g,h   Verdile, G ⁱ   Bharadwaj, P ⁱ   Gupta, V ⁱ   Barr, R ⁱ   Friss, A ^a   Dolios, G ^a   Wang, R ^a   Ringe, D ^e   Fraser, P ^j   Westaway, D ^k   St George Hyslop, P H ^k   Szabo, P ^l   Relkin, N R ^l   Buxbaum, J D ^a,b   Glabe, C G ^m,n   Protter, A A ^h   Martins, R N ^f,i,o   Ehrlich, M E ^a   Petsko, G A ^e,l   Yue, Z ^a   Gandy, S ^a,b,p   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Psychiatry and the Mount Sinai Alzheimer's Disease Research Center ^*  (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d UNIVERSITY OF BONN   (Germany)

^e BRANDEIS UNIVERSITY   (United States)

^f UNIVERSIDAD ANDRÉS BELLO   (Chile)

^g Fundacion Ciencia para la Vida   (Chile)

^h Medivation Inc   (United States)

ⁱ EDITH COWAN UNIVERSITY   (Australia)

^j UNIVERSITY OF TORONTO   (Canada)

^k UNIVERSITY OF ALBERTA   (Canada)

^l WEILL CORNELL MEDICAL COLLEGE   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^o HOLLYWOOD PRIVATE HOSPITAL   (Australia)

^p VETERANS AFFAIRS MEDICAL CENTER   (United States)

more..

Author keywords

Alzheimer's disease; amyloid; autophagy; therapeutics

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AUTOPHAGY PROTEIN 5; DIMEBON; MAMMALIAN TARGET OF RAPAMYCIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATION; BRAIN; CELL CULTURE; COGNITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; FEAR; HUMAN; HUMAN CELL; IMMUNOHISTOLOGY; LEARNING; MACROAUTOPHAGY; MALE; MAMMAL CELL; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; REINFORCEMENT; SIGNAL TRANSDUCTION;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOPHAGY; BRAIN; CELLS, CULTURED; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; INDOLES; MICE; MICE, TRANSGENIC; MICROTUBULE-ASSOCIATED PROTEINS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84881178228     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.106     Document Type: Article

References (35)

1. Wu J, Li Q, Bezprozvanny I. Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 2008; 3: 15
2. Lermontova NN, Lukoyanov NV, Serkova TP, Lukoyanova EA, Bachurin SO. Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000; 129: 544-546
3. Bachurin S, Bukatina E, Lermontova N, Tkachenko S, Afanasiev A, Grigoriev V et al. Antihistamine agent Dimebon as a novel neuroprotector and a cognition enhancer. Ann N Y Acad Sci 2001; 939: 425-435
4. Grigorev VV, Dranyi OA, Bachurin SO. Comparative study of action mechanisms of dimebon and memantine on AMPA-And NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003; 136: 474-477
5. Schaffhauser H, Mathiasen JR, Dicamillo A, Huffman MJ, Lu LD, McKenna BA et al. Dimebolin is a 5-HT6 antagonist with acute cognition enhancing activities. Biochem Pharmacol 2009; 78: 1035-1042
6. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T et al. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-Aspartate receptor antagonism. J Pharmacol Exp Ther 2010; 333: 748-757
7. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-To-moderate Alzheimer's disease: A randomised, double-blind, placebo-controlled study. Lancet 2008; 372: 207-215
8. Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol 2010; 67: 154-160
9. Lermontova NN, Redkozubov AE, Shevtsova EF, Serkova TP, Kireeva EG, Bachurin SO. Dimebon and tacrine inhibit neurotoxic action of beta-Amyloid in culture and block L-Type Ca(2+) channels. Bull Exp Biol Med 2001; 132: 1079-1083
10. Steele JW, Kim SH, Cirrito JR, Verges DK, Restivo JL, Westaway D et al. Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo. Mol Neurodegener 2009; 4: 51
11. Pieper AA, Xie S, Capota E, Estill SJ, Zhong J, Long JM et al. Discovery of a proneurogenic, neuroprotective chemical. Cell 2010; 142: 39-51
12. Abrahamsen H, Stenmark H. Protein secretion: Unconventional exit by exophagy. Curr Biol 2010; 20: R415-R418
13. Boland B, Nixon RA. Neuronal macroautophagy: From development to degeneration. Mol Aspects Med 2006; 27: 503-519
14. Yue Z, Friedman L, Komatsu M, Tanaka K. The cellular pathways of neuronal autophagy and their implication in neurodegenerative diseases. Biochim Biophys Acta 2009; 1793: 1496-1507
15. Butler D, Nixon RA, Bahr BA. Potential compensatory responses through autophagic/lysosomal pathways in neurodegenerative diseases. Autophagy 2006; 2: 234-237
16. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: Effects on cognitive impairments. J Biol Chem 2010; 285: 13107-13120
17. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 2011; 6: E25416
18. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-b. PLoS One 2010; 5: E9979
19. Tian Y, Bustos V, Flajolet M, Greengard P. A small-molecule enhancer of autophagy decreases levels of Abeta and APP-CTF via Atg5-dependent autophagy pathway. FASEB J 2011; 25: 1934-1942
20. Sarkar S, Perlstein EO, Imarisio S, Pineau S, Cordenier A, Maglathlin RL et al. Small molecules enhance autophagy and reduce toxicity in Huntington's disease models. Nat Chem Biol 2007; 3: 331-338
21. Lane RF, Shineman DW, Fillit HM. Beyond amyloid: A diverse portfolio of novel drug discovery programs for Alzheimer's disease and related dementias. Alzheimer's Res Ther 2011; 3: 36
22. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, Bowlby M et al. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2006; 103: 5161-5166
23. Bampton ET, Goemans CG, Niranjan D, Mizushima N, Tolkovsky AM. The dynamics of autophagy visualized in live cells: From autophagosome formation to fusion with endo/lysosomes. Autophagy 2005; 1: 23-36
24. Yang Z, Klionsky DJ. Mammalian autophagy: Core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22: 124-131
25. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998; 273: 14484-14494
26. Morissette G, Lodge R, Bouthillier J, Marceau F. Receptor-independent, vacuolar ATPase-mediated cellular uptake of histamine receptor-1 ligands: Possible origin of pharmacological distortions and side effects. Toxicol Appl Pharmacol 2008; 229: 320-331
27. Broe M, Shepherd CE, Mann DM, Milward EA, Gai WP, Thiel E et al. Insoluble alphasynuclein in Alzheimer's disease without Lewy body formation. Neurotox Res 2005; 7: 69-76
28. Chishti MA, Yang DS, Janus C, Phinney AL, Horne P, Pearson J et al. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J Biol Chem 2001; 276: 21562-21570
29. Bharadwaj P, Verdile G, Barr RK, Gupta V et al. Latrepirdine (Dimebont) enhances autophagy and reduces intracellular GFP-Ab42 levels in yeast. J Alzheimer's Disease (in press
30. Steele JW, Ju S, Lachenmayer L, Liken J, Stock A, Kim SH et al. Latrepirdine stimulates autophagy and reduces accumulation of a-synuclein in cells and in mouse brain. Mol Psychiatry (in press
31. Wang J, Ferruzzi MG, Varghese M, Qian X, Cheng A, Xie M et al. Preclinical study of dimebon on beta-Amyloid-mediated neuropathology in Alzheimer's disease. Mol Neurodegener 2011; 6: 7
32. Knauer MF, Soreghan B, Burdick D, Kosmoski J, Glabe CG. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc Natl Acad Sci USA 1992; 89: 7437-7441
33. Nixon RA, Yang DS. Autophagy failure in Alzheimer's disease-locating the primary defect. Neurobiol Dis 2011; 43: 38-45
34. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 2011; 134: 258-277
35. Caccamo A, Maldonado MA, Majumder S, Medina DX, Holbein W, Magrí A et al. Naturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanism. J Biol Chem 2011; 286: 8924-8932